Dr. Ghosh on the role of standard CAR T-Cell therapy in myeloma
Monalisa Ghosh, MD, discusses the role of standard CAR T cell therapy in patients with multiple myeloma.
Monalisa Ghosh, MD, assistant clinical professor at the University of Michigan, discusses the role of standard CAR T cell therapy in patients with multiple myeloma.
These products are promising in many ways and offer several advantages, including reduced manufacturing time, Ghosh says. Experts in the field can request and receive ready-made CAR T-cell products from a bank, she explains. This eliminates the need to wait for the cells to be collected from the patient, which exposes the patient to some degree of risk, and decreases the manufacturing time which usually takes several weeks. The reduced treatment time may also be of benefit for patients with rapidly progressing disease, notes Ghosh.
However, challenges exist with this therapy, as allogeneic cells can cause certain unwanted effects, such as a graft-versus-host reaction similar to reactions seen with stem cell transplantation, Ghosh explains. Currently, some T cell receptor engineering methods may be able to mitigate this risk, she adds. Additionally, some hosts may reject the cells, a possibility that was observed in early studies, in which the cells did not demonstrate long-term persistence. It may be possible to overcome this with multiple cell infusions, notes Ghosh.
Overall, the accessibility of commercial CAR T cell products to a large group of patients with multiple myeloma appears promising, concludes Ghosh.